Clinical Trial Update: Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and Taxanes [Phase 2]

View source ↗

Summary

Phase II pilot study evaluating cisplatin plus metronomic cyclophosphamide in metastatic triple-negative breast cancer resistant to anthracyclines and taxanes; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Cytoxan (cyclophosphamide)

Snippet

Sponsor: Centre Jean Perrin | Conditions: Metastatic Breast Cancer | Phase 2 | Status: TERMINATED